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Abstract
Development of cervical cancer is a long process of abnormal cancerous cell growth in the cervix and is primarily
the result of infection with specific high-risk types of human papillomavirus (HPV). The cytokines tumor necrosis
factor α (TNFα) and lymphotoxin α (LTA) have an important role in all stages of cervical cancer and have the ability to
induce the regression or promote the development of human tumors. Biologically important single-nucleotide poly-
morphisms (SNPs) occur within the TNFα and LTA genes. Therefore, the purpose of this study was to investigate
the SNPs in the TNFα promoter region (−163, −238, −244, −308, −376, −857, −863, and −1031) and in the first
intron of LTA (+252) in women with precursor lesions of cervical cancer. Overall, we studied 396 women from
Mexico City. A total of 191 patients with HPV infection and precursor cervical lesions were subdivided in two
groups: those with low-grade squamous intraepithelial lesions (n = 132) and those with high-grade squamous
intraepithelial lesions (n = 59). Women (n = 205) negative for HPV and without cervical lesions were also included
in the study. DNA was extracted from peripheral white blood cells and from cervical samples, and detection of
biallelic polymorphisms of TNFα and LTA was performed using the polymerase chain reaction–sequence-specific
oligonucleotide probe and restriction fragment length polymorphism techniques, respectively. We demonstrated
that risk is associated with the genotype G/A (odds ratio = 2.48) and that protection is associated with the genotype
G/G of SNP TNFα −376 (odds ratio = 0.37).
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Introduction
Cervical cancer is the second most common cancer in women world-
wide, but it is the most common one in most developing countries,
where 80% of the cases occur. Cervical cancer is the leading cancer-
related cause of death in Mexico. The principal risk factors are poverty-
related factors, including a lack of formal education, unemployment, a
low socioeconomic level, rural residence, and insufficient access to
healthcare [1]. The most extensively studied aspect of human papillo-
mavirus (HPV) infection has been the molecular pathogenesis of cer-
vical cancer and its precursor lesions, which are frequently referred to as
low- and high-grade squamous intraepithelial lesions (LSIL and HSIL,
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respectively). Certain HPV genotypes, such as HPV-16 and -18, have
been definitively associated with the development of cervical cancer
[2–4]. Although the virus is usually cleared in 70% to 90% of HPV-
infected individuals, in a small percentage of patients, the virus persists
and may lead to the development of SILs [5].
The cellular immune response mediated by cytokines is the main
defense against tumors related to cervical carcinogenesis. Previous
studies have suggested that a T-helper 1 (TH1) response is associated
with the clearance of HPV infection and the regression of cervical
cancer and that TH2 responses are associated with cervical carcino-
genesis owing to the stimulation of tumor growth [6,7]. Although
each study was different in the observed profiles of increased cyto-
kine, the results revealed that both TH1 and TH2 cytokines are in-
creased in cervical cancer. Different studies of candidate genes have
demonstrated that genetic polymorphisms in cytokine genes contrib-
ute to the variation in the levels of cytokines produced, and this varia-
tion may influence the severity of cervical cancer [7,8].
Tumor necrosis factor α (TNFα) and lymphotoxin α (LTA) are
members of the tumor necrosis factor family of cytokines. The TNFα
and LTA genes are located within the major histocompatibility com-
plex, between the HLA class I and II regions on chromosome 6p21.3.
Several studies of different diseases have investigated the effect of
single-nucleotide polymorphisms (SNPs) in the TNFα promoter
region (−163, −238, −244, −308, −376, −857, −863 and −1301)
[9,10] and the NcoI restriction fragment length polymorphism
(+252) in the first intron of LTA [11]. Most SNPs located within
the TNFα promoter region have a change of G to A, as is found at
positions −163, −238, −244, −308, and −376. The −857 and −1031
SNPs have a C-to-T and T-to-C transition, respectively, whereas the
SNP at the −863 position is a C-to-A transition and LTA +252 has
an A-to-G transition. All SNPs within the TNFα promoter and LTA
seem to be biologically important in the transcription of these cytokines
and are associated with various diseases [12,13].
We selected these cytokines for our study because they are involved
in the immune response to diverse forms of cellular stress, inflamma-
tion, and exposure to carcinogens. The objective of this study was to
examine the relationship of genetic polymorphisms in the TNFα
promoter region and in the intronic position of LTA with the devel-
opment of LSIL and HSIL in Mexican women.
Materials and Methods
Studied Population
We studied 396 Mexican women older than 25 years who attended
theMexican Institute of Social Security ofMexico City fromDecember
2003 to July 2006. These women were divided in two study groups.
One group was the controls and consisted of 205 healthy women with a
mean age of 42 years with three Papanicolaou test samples negative for
HPV infection, without SILs, and with normal cytology and colpos-
copy results. Each sample was analyzed at a 1-year interval. The second
group consisted of 191 patients with HPV infection and SILs based on
cytology, histology, and colposcopy examination. The patients in this
group had a mean age of 37 years. This group was subdivided according
to the Bethesda classification [14]: 132 women with LSIL (women
diagnosed with HPV infection and cervical intraepithelial neoplasia 1
[CIN 1]) and 59 women with HSIL (women diagnosed with CIN 2
and CIN 3). Any patient who had received preventive treatment, who
was pregnant or up to 2 months postpartum, with a history of hyster-
ectomy, or with a severe chronic disease was excluded from the study.
Study participants completed an interviewer-administered risk factor
questionnaire that assessed reproductive, sexual, and medical histories
and demographic data.
Genomic and Cervical DNA Extraction
Genomic DNA was extracted from a 5-ml total blood sample drawn
from each woman. DNA was isolated from these cells using a salting-
out microtechnique [15] and was frozen at −20°C until tested.
Cervical cell DNA was extracted from cytologic samples taken from
the cervical transformation zone after colposcopic examination of the
cervix and before the application of acetic acid. The sample was placed
in 1 ml of cold phosphate-buffered saline solution for subsequent DNA
extraction by the standard sodium dodecyl sulfate–proteinase K lysis
technique [16] and was frozen at −20°C until tested.
Polymerase Chain Reaction Detection of HPV
We used two sets of general primers (MY09/MY11 and GP5/GP6)
and the polymerase chain reaction and cycling conditions described
previously for the detection of HPV DNA in cervical cells [17,18].
As a positive control, HPV DNA obtained from the HeLa cell line,
which contains 10 to 50 copies of the HPV-18 L1 ORF, was used [19].
HPV DNA Type Analysis
HPV-positive samples were subsequently assayed for HPV typing
with the HPVFast 2.0 kit (Pharma Gen S.A., Madrid, Spain) according
to the manufacturer’s instructions.
TNFα Promoter Region Typing
A 1355-base pair (bp) fragment of the TNFα promoter region
sequence was amplified with previously published primers [20,21].
Polymerase chain reaction was performed in a reaction mixture con-
taining 0.16 ng of DNA, 0.25 pmol of each primer, 0.03 U of Taq
polymerase (Invitrogen, Carlsbad, CA), 1.5 mM of MgCl2, 0.2 mM
of dNTPs, 16 mM Tris-HCl (pH 8.4), and 50 mM KCl. The
amplification conditions were 94°C for 3 minutes, 64°C for 1 minute,
and 72°C for 1 minute followed by 35 cycles of 94°C for 1 minute,
64°C for 1 minute, and 72°C for 1 minute, and a final cycle of 94°C
for 1 minute, 64°C for 1 minute, and 72°C for 5 minutes.
The samples were genotyped for SNPs within the TNFα promoter
region gene sequence (GenBank accession number Z15026) using
the sequence-specific oligonucleotide probes (SSOP) technique as fol-
lows: −163 (G→A) (without rs number), −238 (G→A) (rs361525),
−244 (G→A) (rs673), −308 (G→A) (rs1800629), −376 (G→A)
(rs1800750), −857 (C→T) (rs1799724), −863 (C→A) (rs1800630),
and −1301 (T→C) (rs1799964).
The −163 (CTTCTCCATCGCGGGGGC), −244 (GATTCC -
GAGGGGGGTCTT), −308 (AACCCCGTCCCCATGCCC),
and −376 (CCTTCTAACTTCGAGACA) probes and their counter-
parts were designed by our laboratory, and the other probes used (−238,
−857, −863, and −1031) have been published elsewhere [22].
Eight SSOP and their counterparts were used to identify the SNPs
in the TNFα promoter region. The experimental conditions for the
SSOPmethod were as described previously [23] with the following mod-
ification for the SNPs in TNFα promoter region. The hybridization tem-
peratures were as follows: 38°C for probes SNP −376[A] and −1031[T];
40°C for probe −376[G]; 43°C for probes −857[T], −863[C], and
−1031[C]; 47°C for probes −244[A], −857[C], and −863[A]; 50°C
for probes −238[A] and −244[G]; 53°C for probes −163[A], −238[G],
and −308[A]; 55°C for probe −163[G]; and 56°C for probe −308[G].
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The stringent wash temperatures were as follows: 50°C for probes
−376[G], −376[A], and −863[C]; 55°C for probe −1031[T]; 57°C
for probe −1031[C]; 58°C for probes −244[A], −857[C], −857[T], and
−863[A]; 62°C for probes −163[G], −163[A], −238[G], −244[G],
−308[G], and −308[A]; and 66°C for probe −238[A]. As a positive con-
trol, we used DNA obtained from a B-lymphoblastoid cell line (Boleth)
included in the International Histocompatibility Workshop cell lines
panel [24].
LTA +252 Typing
The DNA samples were genotyped for the polymorphism within
the intronic region gene sequence of LTA +252 (A→G) (rs909253)
(GenBank accession number Z15026) using the restriction fragment
length polymorphism technique. We used previously published 5′
and 3′ primers and cycling conditions [25].
Statistical Analysis
The allele and genotype frequencies were compared between the
control and patient groups (LSIL and HSIL). Significant associations
were evaluated by either the χ2 test or the Fisher exact test with 2 × 2
contingency tables using the Epi Info 6.04D 2001 USA program.
The level of significance was established at P < .05. The magnitude
of the associations was assessed using the odds ratio (OR), and 95%
of confidence intervals (CI) were calculated for the OR [26]. The
gene-dose effect was determined with a linear trend analysis using the
dominant homozygote genotype for each SNP studied, and the χ2 test
was performed using the Epidat 3.1 Software [27], with a level of
significance at P < .05. The attributable proportion (AP) value was
calculated using the formula: AP = PRF × (1 − 1 / OR), in which
PRF represents percentage of risk factor [28]. A χ2 analysis was used
to test for any deviation of the genotype distribution from Hardy-
Weinberg equilibrium. Haplotypes of the TNFα and LTA SNPs were
assessed using HaploView 4.1 Software [29].
Results
Study Population
A total of 396 women were typed for SNPs in the promoter region
of TNF and LTA. From this group, 205 women who were negative
for HPV and who had no SILs were selected as the control group.
From the 191 HPV-positive patients, 132 had LSIL and 59 had HSIL.
Thirteen types of HPV were detected (6, 11, 16, 18, 31, 45, 53, 55, 56,
58, 82, 83, and 90), and 18 samples were negative for HPV infection in
the patient group (3 in LSIL and 15 in HSIL). Infection with HPV
type 16 was the most common at 50.74% and 48.83% in LSIL and
HSIL, respectively. This result was followed by type 58 at 12.68% and
17.74% and type 18 at 8.95% and 14.52% in LSIL and HSIL, respec-
tively. In one sample, we found a coinfection of two HPV types (6 and
82). All of the samples studied were in Hardy-Weinberg equilibrium
for all SNPs analyzed, and there were no statistically significant differ-
ences when the frequencies of the observed and expected genotypes
were compared.
Polymorphisms in the Promoter Region of TNFα
The distribution of alleles and genotypes of the polymorphisms in
the promoter region of TNFα in patients and controls is shown in
Table 1. A comparison between the allele frequencies of the controls
and patients was performed, and the results showed that, in patients
with LSIL, the TNFα −376 “A” allele is associated with the develop-
ment of LSILs (P < .05, OR = 2.81, 95% CI = 1.09-7.44). In both
patients and controls, the genotype G/G was the most frequent at
positions −163, −238, −244, −308, and −376; the C/C genotype
was present at −857 and −863, whereas genotypes T/T and A/A were
defined at positions −1031 and +252, respectively. There were no dif-
ferences in the distribution of the genotype frequencies at positions
−163, −238, −244, −308, −857, −863, and −1031 of the promoter
region of TNFα. However, we observed a risk trend for the TNFα
−376 position (P < .05, OR = 2.48, 95% CI = 0.98-6.25) in the
genotype G/A by comparing the LSIL group with the control group
(Table 1). The calculated AP value was 5.45%, indicating that approx-
imately 5% of patients with LSIL may be predisposed to the devel-
opment of cervical lesions under the influence of allele “A.” When
the frequencies of the heterozygous and homozygous genotypes of the
SNPs in the promoter region of TNFα and LTA were grouped, the
genotype G/G at the TNFα −376 position was significantly different
(P < .05, OR = 0.37, 95% CI = 0.14-0.99) in patients with LSIL. By
analyzing the genotypes of the TNFα promoter region for HPV infec-
tion, we found no association between HPV-positive patients and
HPV-negative patients as well as between HPV-negative patients and
controls (data not shown).
The LTA +252 Polymorphism
The frequency distributions of the alleles and genotypes at position
+252 of the LTA gene in the control group and patients are shown in
Table 1. In the control group and LSIL, the most common genotype
was A/A at 44.87% (92/205) and 45.45% (60/132), respectively, whereas
the frequency of genotype A/G was more frequent (54.23%) in patients
with HSIL. There was no statistically significant association between
any of the polymorphisms of the alleles and genotypes of the LTA
+252 position and the risk of developing SILs when the three groups
were compared. When the frequencies of the recessive homozygous
(G/G) and heterozygous (A/G) genotypes at position +252 of LTA
were grouped, no statistically significant differences were observed
between patients with LSIL and HSIL and the control group (Table 1).
By comparing the LTA +252 position polymorphism and the HPV
infection status, we found that the allele “G” was not statistically sig-
nificant in patients with SILs regardless of a positive or negative HPV
status (data not shown).
Combined TNFα Promoter Region and LTA Genotypes
We tested whether combinations of the genotypes of the promoter
region of TNFα and LTA were related to susceptibility or protection
in the patient groups (LSIL andHSIL) compared with the control group.
Although 56 different genotype combinations are possible, only 20 were
significant (data not shown). In contrast, the combination genotype G-
G/G-G/G-G/G-G/G-G/C-T/C-C/T-T/G-A showed a trend of risk for
HSIL, although the result was not significant (P = .052; Table 2).
Haplotypes
A total of eight SNPs across the TNFα/LTA loci were analyzed.
Figure 1 shows the linkage disequilibrium (LD plot) of the SNPs in
the TNFα/LTA genes of patients with LSIL (Figure 1A) and HSIL
(Figure 1B). Table 3 shows the association analysis of the eight SNPs
across the TNFα/LTA loci established in healthy women (controls)
and in patients with LSIL and HSIL. Three haplotype blocks were
identified, with 10 haplotypes for the control group, 8 haplotypes in
patients with LSIL, and 7 haplotypes for patients with HSIL. The
ATCCGGGG haplotype was the most frequent in all of the groups.
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It was observed in 30.8% of control subjects, 45.6% of patients with
LSIL, and 34.0% of patients with HSIL. We found that the haplotypes
GTCTGGGG and ATCCGGGG were more frequent in the patient
groups (45.6% and 25.4% in LSIL and 34.0% and 21.1% in HSIL,
respectively), but only the GTCTGGGG genotype was associated with
an eight-fold increase in risk of LSIL development (P < .05, OR = 8.33,
95% CI = 5.12-13.61). For patients with HSIL, the risk increased by
almost four-fold (P < .05, OR = 3.85, 95% CI = 2.05-7.23). In
Table 1. TNFα Promoter Region and LTA SNP Polymorphisms Frequencies in the Control Group and in Patients with LSIL and HSIL.
SNP Site/Allele Genotype Control, n (%) LSIL, n (%) OR* (95% CI) HSIL, n (%) OR† (95% CI)
TNFα
−163
G 403 (98.59) 264 (100.0) 118 (100.0)
A 7 (1.70) 0 (0.0) 0 (0.0)
GG 198 (96.58) 132 (100.0) Reference 59 (100.0) Reference
GA 7 (3.14) 0 (0.0) — 0 (0.0) —
Carrier A 7 (3.14) 0 (0.0) — 0 (0.0) —
−238
G 403 (98.30) 264 (100.0) 118 (100.0)
A 7 (1.70) 0 (0.0) 0 (0.0)
GG 199 (97.07) 132 (100.0) Reference 59 (100.0) Reference
GA 5 (2.93) 0 (0.0) — 0 (0.0) —
AA 1 (0.48) 0 (0.0) — 0 (0.0) —
Carrier A 6 (2.92) 0 (0.0) — 0 (0.0) —
−244
G 404 (98.53) 261 (98.86) 118 (100.0)
A 6 (1.46) 3 (1.13) 0 (0.0)
GG 199 (97.07) 129 (97.72) Reference 59 (100.0) Reference
GA 6 (2.93) 3 (2.27) — 0 (0.0) —
Carrier A 6 (2.92) 3 (2.27) NS 0 (0.0) —
−308
G 387 (94.40) 250 (94.69) 115 (97.45)
A 23 (5.60) 14 (5.30) 3 (2.54)
GG 183 (89.26) 122 (92.42) Reference 56 (94.91) Reference
GA 21 (10.24) 10 (7.57) NS 3 (5.08) NS
AA 1 (0.48) 0 (0.0) — 0 (0.0) —
Carrier A 22 (10.73) 10 (7.57) NS 3 (5.08) NS
−376
G 402 (98.04) 250 (94.69) 117 (99.15)
A 8 (1.95) 14 (5.30) 1 (0.84)
GG 197 (96.09) 119 (90.15) Reference 58 (98.30) Reference
GA 8 (3.90) 12 (9.09) 2.48 (0.98-6.25)‡ 1 (1.69) —
AA 0 (0.0) 1 (0.75) — 0 (0.0) —
Carrier A 8 (3.90) 13 (9.85) NS 1 (1.69) NS
−857
C 304 (74.14) 186 (70.45) 83 (70.33)
T 106 (25.85) 78 (29.54) 35 (29.66)
CC 114 (55.60) 63 (47.72) Reference 30 (50.84) Reference
CT 76 (37.07) 59 (44.69) NS 23 (38.98) NS
TT 15 (7.31) 10 (7.57) NS 6 (10.16) NS
Carrier T 91 (44.40) 69 (52.28) NS 29 (49.15) NS
−863
C 360 (87.80) 237 (89.77) 110 (93.22)
A 50 (12.19) 27 (10.22) 8 (6.77)
CC 160 (78.04) 106 (80.30) Reference 52 (88.13) Reference
AC 40 (19.51) 25 (18.93) NS 6 (10.16) NS
AA 5 (2.43) 1 (0.75) NS 1 (1.69) NS
Carrier A 45 (21.95) 26 (19.70) NS 7 (11.87) NS
−1031
T 345 (84.14) 223 (84.46) 102 (86.44)
C 65 (15.85) 41 (15.53) 16 (13.55)
TT 147 (71.70) 93 (70.45) Reference 45 (76.27) Reference
CT 51 (24.87) 37 (28.03) NS 12 (20.33) NS
CC 7 (3.41) 2 (1.51) NS 2 (3.38) NS
Carrier C 58 (28.30) 29 (29.55) NS 14 (23.73) NS
LTA
+252
A 273 (66.58) 176 (66.66) 74 (62.71)
G 137 (33.41) 88 (33.33) 44 (37.28)
AA 92 (44.87) 60 (45.45) Reference 21 (35.59) Reference
AG 89 (43.41) 56 (42.42) NS 32 (54.23) NS
GG 24 (11.70) 16 (12.12) NS 6 (10.16) NS
Carrier G 113 (55.13) 72 (54.55) NS 38 (64.40) NS
NS indicates that the P value is not significant.
*Odds ratio calculated by comparing LSIL versus control.
†Odds ratio calculated by comparing HSIL versus control.
‡P < .05.
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contrast, the haplotypes ACACGGGG and ATCCGGGG presented a
low-grade risk of only four-fold (P < .05, OR = 4.36, 95% CI = 3.09-
6.15) and almost three-fold (P < .05, OR = 2.68, 95% CI = 1.09-
6.75), respectively, for developing cervical lesions. The ATCTGGGG
haplotype was associated with a protective effect against lesion de-
velopment (P < .05, OR = 0.39, 95% CI = 0.21-0.70). The
ATACGGGG haplotype was related to protective effects in patients
with LSIL (P < .05, OR = 0.19, 95% CI = 0.06-0.59), whereas in
patients with HSIL, this haplotype yielded a two-fold increase in sus-
ceptibility to developing high-grade lesions (P < .05, OR = 2.43, 95%
CI = 1.26-4.69; Table 3).
Discussion
Human Papillomavirus
The frequency of HPV-16 in our study (50.0%) was similar to the
frequency found in women with HSIL (reported as CIN grades 2
and 3) in South Africa (56.6%) [30]. We confirmed that infection
with HPV-16 remains one of the main factors predisposing to the
development of SILs and cervical cancer. Interestingly, the HPV type
58 was the second most common virus in the samples (14.28%),
similar to what has been observed in other countries, such as Africa
(12.8%) [31] and Jamaica (18.8%) [32]. González-Losa [33] found
that, in women diagnosed with LSIL and HSIL in the state of
Yucatan (in the southeast of Mexico), HPV type 58 was the most
frequent (23.3% and 30.6% in LSIL and HSIL cases, respectively),
whereas in women treated for dysplasia in clinics of the Mexican
Social Security Institute in the state of Nayarit (Western Mexico),
the frequency of this type was 12.12% [34]. These data demonstrate
that, although there are different distribution patterns of the types of
HPV in different countries and even within the same country, HPV
type 58 is one of the most common causes of cervical and vaginal
infections and is a precursor for cervical lesions and cancer. Our re-
sults provide further evidence of the distribution of the most frequent
HPV types in an area of Mexico City, and this information could be
Table 2. Genotypes Relevant to Risk.
Genotypes Control, n = 205 (%) LSIL, n = 132 (%) OR* (95% CI) HSIL, n = 59 (%) OR† (95% CI)
G-G/G-G/G-G/G-G/G-G/C-C/C-C/T-T/G-A 22 (10.73) 13 (9.84) — 9 (15.25) 1.50 (0.60-3.69)
G-G/G-G/G-G/G-G/G-G/C-T/C-C/T-T/A-A 22 (10.73) 21 (15.9) 1.57 (0.79-3.14) 7 (11.86) 1.12 (0.41-2.96)
G-G/G-G/G-G/G-G/G-G/C-T/C-C/T-T/G-A 22 (10.73) 18 (13.63) 1.31 (0.64-2.68) 12 (20.33) 2.12 (0.91-4.89)‡
G-G/G-G/G-G/G-G/G-G/C-C/C-C/T-T/G-G 17 (8.29) 11 (8.33) 1.01 (0.42-2.36) 6 (10.16) 1.25 (0.42-3.60)
G-G/G-G/G-G/G-G/G-G/T-T/C-C/T-T/A-A 15 (7.31) 8 (6.06) — 5 (8.47) 1.17 (0.35-3.66)
G-G/G-G/G-G/G-G/G-G/C-C/A-C/T-C/A-A 7 (3.41) 6 (4.54) 1.35 (0.39-4.58) 2 (3.38) —
G-G/G-G/G-G/G-G/G-G/C-T/A-C/T-C/A-A 7 (3.41) 9 (6.81) 2.07 (0.68-6.35) 1 (1.69) —
G-G/G-G/G-G/G-G/G-G/C-C/A-C/T-C/G-A 6 (2.92) 8 (6.06) 2.14 (0.66-7.14) 3 (5.08) 1.78 (0.34-8.34)
G-G/G-G/G-G/G-A/G-G/C-C/C-C/T-T/G-A 5 (2.43) 3 (2.27) — 3 (5.08) 2.14 (0.39-10.71)
G-G/G-G/G-G/G-G/G-G/C-C/C-C/T-C/G-A 4 (1.95) 1 (0.75) — 3 (5.08) 2.69 (0.46-14.78)
G-G/G-G/G-G/G-G/G-G/C-T/C-C/T-C/A-A 2 (0.97) 2 (1.51) 1.56 (0.16-15.70) 2 (3.38) 3.63 (0.36-36.98)
G-G/G-G/G-G/G-G/G-A/C-C/C-C/T-T/G-A 1 (0.48) 1 (0.75) 1.56 (0.0-57.45) 1 (1.69) 3.52 (0.0-130.89)
*Comparisons between LSIL and the control group.
†Comparisons between HSIL and the control group.
‡P = .052.
Figure 1. Linkage disequilibrium plot of SNP estimated as r2 using Haploview 4.1. (A) LD plot for patients with LSIL. (B) LD plot for
patients with HSIL.
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used for the formulation of appropriate vaccines to combat specific
HPV infections among Mexican women.
SNPs in the Promoter Region of TNFα
Most genetic association studies of TNFα with diseases in differ-
ent patient populations have been conducted with different SNPs in
the promoter regions of TNFα and LTA [35,36]. In our study, most
SNPs examined were in the promoter region of TNFα (−163, −238,
−244, −308, −376, −857, −863 and −1031) and at position +252 of
the first intron of LTA to acquire a more complete perspective of the
associations of SNPs in TNFα and LTA with the development of
precursor lesions of cervical cancer in Mexican women.
Some studies have suggested that polymorphisms of SNPs in the
promoter region of TNFα may be a contributing factor for the devel-
opment of cervical cancer [37,38]. However, in our study, the SNPs
at TNFα −163, −238, −244, −308, −857, −863, and −1031 showed
no association with SILs.
When comparing the TNFα −163 and −244 SNP genotype fre-
quencies from our study with those of two other studies, one with
Hispanic women with invasive cervical cancer and HPV-16–positive
tumors (TNFα −161, 100%-G/G, 0.0%-G/A, and 0.0%-A/A; and
TNFα −243, 99.2%-G/G, 0.8%-G/A, and 0.0%-A/A) [38] and
one from patients with cervical cancer treated at the Mayo Clinic
(US population) (TNFα −244, 100%-G/G, 0.0%-G/A and 0.0%-A/A)
[37], only minimal differences are observed. This information might
indicate that the frequencies observed in the three populations are very
similar. When we compared our results against TNFα −244 sarcoidosis
patients in Hokkaido, Japan [25], and patients of the Irani National
Reference Laboratory for Tuberculosis [39], we noted that both of
the other populations presented only the genotype G/G, whereas our
population also had the genotype G/A, with a 2.93% frequency.
Another possible explanation may be the fact that the TNFα −244
SNP has been reported to be the first SNP of TNFα that is correlated
to extended HLA haplotypes of African origin, which may indicate
that this SNP of TNFα is highly conserved even after several years of
migration [40].
The SNPs TNFα −238 and −308 have been intensively studied in
patients with precursor lesions of cervical cancer and invasive cervical
cancer, and the genotype G/G is the most frequent in different pop-
ulations, such as the United Kingdom (89.0% and 52.0%) [41],
New Delhi (96.0% and 91.0%) [42], and Switzerland (95.3% and
83.3%) [43]. With other diseases, the frequency of the genotype G/G
for the same SNPs was more frequent, as evidenced by a report in a
Mexican population of patients with systemic lupus erythematosus
(92.7% and 94.5%) [44], another report on UK women with breast
cancer (87.7% and 62.9%) [45] and, finally, a study of patients with
recurrent spontaneous absorption in the Chinese population (88.8%
and 90.8%) [35]. Although we confirmed that the genotype G/G
was the most frequent in both SNPs, we found no statistically signifi-
cant association between either SNP and the development of precursor
lesions. In our study, the TNFα −238 SNP genotype was present only
as the homozygous G/G (dominant) genotype in all patients (LSIL and
HSIL). In other populations, it has been shown that the genotype G/G
was prevalent, whereas genotypes that carry the recessive allele (G/A
and A/A) have lower frequencies (1%-14%), depending on the study
population [37,38,41–43]. The genotype G/A for the TNFα −238 SNP
has been associated with a protective role in cervical cancer patients in
the United States (OR = 0.33, 95% CI = 0.11-0.96) [37], whereas for
patients in North Korea, the TNFα −238 allele “A” is associated with a
decreased risk of developing different types of cancer (cervical, gastric,
and renal carcinoma) (OR = 0.25, 95% CI = 0.10-0.64) [46]. When
considering the genotypes that carry the allele “A” in the TNFα −308
(G/A and A/A) recessive position, we found that the genotype frequen-
cies were lower among patients with LSIL and HSIL when compared
with the frequencies of the control group. This finding resembles the
decrease in the TNFα −308 genotype frequencies observed in UK pa-
tients with cervical precursor lesions; in that study, Kirkpatrick et al.
[41] found that this SNP indicates a susceptibility for developing low
dysplasia (P < .05). Other studies have shown that patients with the
allele “A” and the genotype G/A + A/A have an up to two times higher
risk to develop cervical cancer, as demonstrated for a population inNew
Delhi (OR = 2.7, 95% CI = 1.41-5.15) [42] and in India (OR = 2.24
for genotype G/A and OR = 2.05 for genotype A/A) [47] and in
northern Portugal (OR = 1.88, 95% CI = 1.20-2.94) [28]. The differ-
ences in the allele and genotype frequencies of these SNPs in our results
and earlier data are probably explained by the statistical power of the
samples studied or by ethnic differences between the populations.
With respect to the TNFα −376 position, our data showed that
9.09% (12/132) of patients with LSIL had the genotype G/A com-
pared to 3.90% (8/205) in the control group. This difference was sta-
tistically significant (P < .05; Table 1). To date, there is uncertainty
about the biologic effect of the TNFα −376 SNP. However, this SNP
is located in the promoter region of TNFα gene. Knight et al. [48]
suggested that this SNP induces multiple DNA-protein interactions
Table 3. Common Haplotypes and Association Analysis for the Control Group and the LSIL and HSIL Groups.
Haplotypes Control* (%) LSIL* (%) χ2 P OR† (95% CI) HSIL* (%) χ2 P OR‡ (95% CI)
ATCCGGGG 30.8 45.6 15.97 6.43e − 05 4.36 (3.09-6.15) 34.0 2.93 0.0867 —
GTCCGGGG 15.3 7.9 8.74 0.0031 — 13.5 2.33 0.1263 —
ATCTGGGG 15.1 4.5 20.27 6.70e − 06 0.39 (0.21-0.70) 8.5 1.02 0.3122 —
ATACGGGG 7.3 1.0 13.50 2.00e − 04 0.19 (0.06-0.59) 16.2 30.10 4.09e − 08 2.43 (1.26-4.69)
GTCTGGGG 6.7 25.4 50.99 9.26e − 13 8.33 (5.12-13.61) 21.1 0.19 0.6626 3.85 (2.05-7.23)
ACCCGGGG 5.6 6.4 0.22 0.6363 — 1.7 5.37 0.0204 —
GCCCGGGG 4.4 0.0 12.55 4.00e − 04 — 0.0 4.77 0.0289 —
GTCCGAGG 3.9 0.0 10.83 0.001 — 1.7 0.05 0.8133 —
ACACGGGG 2.2 3.9 1.61 0.2041 2.68 (1.09-6.75) 0.0 5.80 0.016 —
ACCTGGGG 2.0 0.0 5.34 0.0208 — 0.0 2.16 0.1415 —
ACACAAGG§ 0.0 2.7 10.98 9.00e − 04 — 0.0 — — —
*Frequency of haplotype.
†Comparison between the LSIL and control groups; all significant data are shown (P < .05).
‡Comparison between the HSIL and control groups; all significant data are shown (P < .05).
§Haplotype only found in patients with LSIL.
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and that it is the less common allele (TNFα −376 “A”) and recruits
the transcription factor Oct-1 to that area. Oct-1 is a transcription
factor whose interactions with other proteins control diverse effects
on gene regulation. In most cases, it enhances transcription, but in
some other contexts, it functions as a transcription repressor [49].
The importance of the potential activity of the transcription factor
Oct-1 in association with the allele “A” of the TNFα −376 SNP was
indicated in a study in which this interaction resulted in an increase of
four times the risk of cerebral malaria in two genetically distinct popu-
lations in Africa (Gambia and Kenya) [48]. It is known that the SNPs
located in the promoter region of different genes can alter the affinity of
association of transcription factors. Therefore, based on our results, the
genotype G/A at the TNFα −376 position likely confers a susceptibility
to develop low-grade precursor lesions by a modification of the tran-
scription product from the allele “A.” This idea is supported by the
value obtained from AP, which indicates that approximately 5% of
patients with LSIL may develop this injury under the influence of allele
“A.”Moreover, when the genotypes were grouped (G/A and A/A), our
results show that the genotype G/G yields protection for the devel-
opment of LSIL (P < .05, OR = 0.37, 95% CI = 0.14-0.99). Calhoun
et al. [37] studied four SNPs of the TNFα promoter region in patients
with cervical cancer, one of which was the TNFα −376 SNP, which is a
risk factor for cervical cancer development. Our findings lead us to pro-
pose that the TNFα −376 SNP may be a susceptibility factor from the
early stages of precursor lesions to cervical cancer.
We noted that genotypes with the recessive allele “T” (C/T and T/T)
at the position TNFα −857 were associated with a protective trend,
as Deshpande et al. [38] described in Hispanic women with cervical
cancer. However, in the same study, the genotypes A/C and A/A at
position TNFα −863 opposed our results (there is a risk trend; Table 1).
In both positions, the data were not statistically significant, possibly
because the number of samples analyzed in our group of patients.
However, Ivansson et al. [43] reported that position −857 of TNFα
and other SNPs had no association with cervical cancer, although it
was a study with sufficient power to detect these associations.
Different studies have indicated a relationship between the expres-
sion of the cytokine TNFα and the SNPs −857 (C/T) and −863 (C/A)
of the TNFα gene promoter region, suggesting that the recessive alleles
−857 “C” and −863 “A” lead to higher production of TNFα, whereas
the other alleles, −857 “T” and −863 “C,” produce lower levels of this
cytokine [9,50]. The allele “T” of TNFα−857, contains an anchor site
for the transcription factor Oct-1 (ATGAAGAC) from position −858 to
position −851 (the −857 SNP is underlined and in bold). The anchor
sequence is present only with the allele “T” but not with the allele
“C,” thereby altering the transcriptional activity of the TNFα gene
[51,52]. We observe that the frequencies of the C/T and T/T geno-
types at position TNFα −857 in patients with LSIL and HSIL were
increased, and we propose that the cells transformed after HPV infec-
tion avoid the host immune system in the early stages of carcinogenesis
and become resistant to TNFα cytotoxicity. Alternatively, some reports
suggest that C changes to an A at position −863 of the promoter region
of TNFα, resulting in an increase in the production of the cytokine
owing to the higher affinity of the transcription factor NF-κB for the
allele “A.” The transcription factor NF-κB is produced in two forms:
one form is the canonical p65-p50 heterodimer, and the other form is a
p50-p50 homodimer. The latter competitively inhibits the transcrip-
tion factor NF-κB when anchored to the allele “A” position TNFα
−863 [53]. The transcription factor NF-κB with the DNA anchor site
is a transcriptional repressor in the promoter region of the TNFα gene
[52,54]. We observed that the frequencies of the genotypes C/A and
A/A in the TNFα −863 position in patients with LSIL and HSIL were
reduced, and there was a trend of risk. These data lead us to conclude
that TNFα production is insufficient and, therefore, is unable to destroy
malignant cells.
The polymorphism at position TNFα −1031 has been associated
with increased transcriptional activity and cytokine production of
TNFα in different studies [22,55]. We observed no significant differ-
ences in the allele and genotype frequencies at this position between
controls and patients with LSIL and HSIL, although this is the first
report that examined the allele and genotype frequencies of TNFα
−1031 position for this population. Our data are similar to the results
of Negoro et al. [56], who studied this SNP in a Japanese population
with Crohn disease. The TNFα −1031 SNP has been associated with
other diseases, such as advanced stage endometriosis [57] and sponta-
neous deep intracerebral hemorrhage [58]. However, we propose that
this position is not associated with the development of precursor lesions
of cervical cancer. Further research is needed to determine the func-
tional significance of this polymorphism for other diseases and different
populations (ethnic groups).
Lymphotoxin α
When the LTA +252 polymorphism was studied, no association
was established with precursor lesions of cervical cancer. This SNP has
also been studied in patients with sarcoidosis, testicular germ cell
tumors, chronic obstructive pulmonary disease, and tuberculosis in
different populations [25,59–61]. We recently reported that the allele
“A” predisposes patients to gastric cancer development [36]. How-
ever, the reported frequencies were different in this study, possibly
because of the selection criteria used for the control subjects, which
were the absence of gastroduodenal symptoms and sex (only females),
leading to a bias in the frequencies.
Our frequencies of the genotypes G/G, G/A, and A/A for LTA
position +252 (44.87%, 43.41%, and 11.70%) were similar to those
of populations in northern Sweden (46.0%, 44.0%, and 11.0%) [59]
and in the United States (43.1%, 44.4%, and 12.5%) [60], and we
found no significant association of this SNP with the development of
testicular germ cell tumors and chronic obstructive pulmonary dis-
ease. In contrast, Niwa et al. [62] studied positions +252 (G→A)
and +804 (C→A) of LTA and found that there is a linkage disequi-
librium between these two positions; the LTA +804 SNP was associ-
ated with a decreased cervical cancer risk, especially for squamous cell
cervical cancer. These data suggest that position +252 is probably not
associated with the development of precursor lesions of cervical cancer.
Another study with a larger number of samples that was performed in
Swiss women found no association between SNP +252 of LTA and
women diagnosed with cervical tumors, severe dysplasia, and in situ
and invasive cervical cancer [43]. Because of the above data, we suggest
that other SNPs of the LTA gene should be considered in future studies
to find possible associations with the development of SILs.
Genotype Combinations
The differences in the genotype combination frequencies between
groups in our study showed no statistical significance, indicating that
the genotype frequencies are not related to the development of cervi-
cal cancer precursor lesions. However, we noted that most genotypes
showed a trend toward susceptibility, and the genotype G-G/G-G/G-
G/G-G/G-G/C-T/C-C/T-T/G-A had an increased frequency as the
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degree of injury advanced. This finding suggests that this genotype
combination could be used as factor for risk surveillance.
Haplotypes
We studied the association of haplotypes including the SNPs of
TNFα and LTA with the susceptibility for the development of cer-
vical cancer precursor lesions. Ivansson et al. [43] reported that the
SNPs −857, −572, −308, and −238 in the TNFα promoter region
and LTA +252 in a Swiss population were not associated with the
development of cervical cancer. We selected SNPs of the TNFα gene
promoter region and the LTA gene based on their involvement in mod-
ifying the transcription of cytokines TNFα and LTA. Our results indi-
cate that the haplotype GTCTGGGG is a potential genetic marker of
a poor prognosis for the development of precursor lesions of cervical
cancer. Most of the composition of this haplotype consists of alleles that
produce fewer transcripts for the cytokines TNFα and LTA, possibly
suggesting that the immune response is inefficient in cervical cells in-
fected by HPV. In contrast, the statistical values observed for the
haplotypes ATACGGGG and ATCTGGGG suggest that they could
be considered protective genetic markers that differentiate progression
in patients with low-grade lesions (LSIL). In this case, the immune re-
sponse is still able to eliminate a certain number or volume of altered
cells infected by HPV. Because the ATCCGGGG and ACACGGGG
haplotypes are risk factors for patients with low injury, whereas the
haplotype ATACGGGG is for patients with high-grade lesions, it is
unlikely that the immune response of women is so efficient as to elim-
inate the altered cells infected by HPV.
In conclusion, our data provide evidence for the association of the
TNFα −376 SNP and the GTCTGGGG and ATACGGGG haplo-
types with the development of precursor lesions, and thus, these
markers might serve as genetic markers of susceptibility. This study
also illustrates the diversity in the effects of the TNFα and LTA
SNPs in a Mexican population sample and the need to conduct fur-
ther studies.
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